Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
The Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan.
BMJ Open. 2019 Oct 22;9(10):e031305. doi: 10.1136/bmjopen-2019-031305.
Clinical trials (CTs) are considered an important method for developing new treatments and providing access to potentially effective drugs that are still under investigation. Measuring the public's knowledge of and attitudes toward CTs is important for assessing their readiness for and acceptance of human drug testing, which has previously not been assessed in the Kingdom of Saudi Arabia (KSA). The objective of this study is to explore the Saudi public's knowledge of and attitudes toward CTs as well as participation in trials to test new or approved drugs.
Cross-sectional.
The 2016 Al Jenadriyah cultural/heritage festival in Riyadh, KSA.
Participating booths and exhibition halls, as well as festival visitors, were approached to participate in the study.
Knowledge of and attitudes toward CTs.
The final number of participants was 938. The responses were converted to a percentage mean score (out of 100) for each knowledge-related response and attitude. The total mean knowledge score was 56.8±24.8 and the attitude-related score was 61.5±28.0. Although most of the participants supported testing approved or off-label and new drugs on adult and paediatric patients, only a third (30.5%) agreed that new drugs could be tested on healthy volunteers. The results indicated that gender, educational level, income, medical background, age and health insurance were independently associated with the level of knowledge of CTs. In terms of attitudes toward CTs, the factors that were independently associated were gender, educational level and medical background.
The Saudi public has a low level of knowledge and a moderately positive attitude toward CTs. There is a moderate positive correlation between the two factors such that as knowledge of CTs increases, the Saudi public will hold more positive attitudes toward CTs.
临床试验（CT）被认为是开发新疗法和提供仍在研究中的潜在有效药物的重要方法。衡量公众对 CT 的了解和态度对于评估他们对人体药物测试的准备程度和接受程度非常重要，而这在沙特阿拉伯王国（KSA）尚未得到评估。本研究旨在探讨沙特公众对 CT 的了解和态度，以及参与测试新的或已批准药物的试验。
横断面研究。
沙特阿拉伯利雅得的 2016 年 Jenadriyah 文化/遗产节。
参与的摊位和展览厅以及节日游客都被邀请参与研究。
对 CT 的了解和态度。
最终参与者人数为 938 人。将每个与知识相关的反应和态度的反应转换为百分比平均值（满分 100 分）。总的平均知识得分为 56.8±24.8，态度相关得分为 61.5±28.0。尽管大多数参与者支持在成人和儿科患者身上测试已批准或非标签和新药，但只有三分之一（30.5%）同意可以在健康志愿者身上测试新药。结果表明，性别、教育水平、收入、医学背景、年龄和医疗保险与 CT 知识水平独立相关。就 CT 态度而言，独立相关的因素是性别、教育水平和医学背景。
沙特公众对 CT 的了解程度较低，对 CT 的态度呈中等偏正面。这两个因素之间存在中度正相关，随着对 CT 的了解程度的提高，沙特公众对 CT 的态度将更加积极。
